170 related articles for article (PubMed ID: 7472782)
21. Immunophenotype, ras oncogenes and p53 onco-suppressor gene in benzo(a)pyrene induced malignant soft tissue tumours in Wistar rats.
Stefanou DG; Nonni AV; Kalpouzos G; Evangelou A; Agnantis NJ
In Vivo; 1998; 12(5):511-21. PubMed ID: 9827359
[TBL] [Abstract][Full Text] [Related]
22. [The significance of p53 gene mutations and expressions in human colorectal tumors].
Qian H; Yu B; Zhou X
Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):332-5. PubMed ID: 8697968
[TBL] [Abstract][Full Text] [Related]
23. p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer.
Nayak BK; Baral RN; Das BR
Neoplasma; 1996; 43(5):305-10. PubMed ID: 8996549
[TBL] [Abstract][Full Text] [Related]
24. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma.
Zhai YL; Nikaido T; Orii A; Horiuchi A; Toki T; Fujii S
Gynecol Oncol; 1999 Dec; 75(3):453-9. PubMed ID: 10600306
[TBL] [Abstract][Full Text] [Related]
25. Alterations of p53 gene in primary gastric cancer tissues.
Hong SI; Hong WS; Jang JJ; Lee DS; Cho NS; Jung ME; Kim HB; Ha GW; Park IC; Cho DS
Anticancer Res; 1994; 14(3B):1251-5. PubMed ID: 8067692
[TBL] [Abstract][Full Text] [Related]
26. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
27. Significance of p53 expression in immature teratomas.
Charoenkwan P; Senger C; Weitzman S; Sexsmith E; Sherman CG; Malkin D; Thorner PS
Pediatr Dev Pathol; 2002; 5(5):499-507. PubMed ID: 12202994
[TBL] [Abstract][Full Text] [Related]
28. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
29. [Detection of p53 gene mutation in paraffin-embedded asbestos-related lung cancer tissue].
Fu D; Liu B; Wang H
Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Jul; 31(4):206-8. PubMed ID: 9812577
[TBL] [Abstract][Full Text] [Related]
30. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
31. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
32. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
33. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.
Waggoner SE; Anderson SM; Luce MC; Takahashi H; Boyd J
Gynecol Oncol; 1996 Mar; 60(3):339-44. PubMed ID: 8774636
[TBL] [Abstract][Full Text] [Related]
34. Detection of loss of heterozygosity of p53 gene in paraffin-embedded breast cancers by non-isotopic PCR-SSCP.
Chen YH; Li CD; Yap EP; McGee JO
J Pathol; 1995 Oct; 177(2):129-34. PubMed ID: 7490678
[TBL] [Abstract][Full Text] [Related]
35. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
36. p53 alterations in chemically induced hamster cheek-pouch lesions.
Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
[TBL] [Abstract][Full Text] [Related]
37. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
39. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
40. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours.
Soini Y; Vähäkangas K; Nuorva K; Kamel D; Lane DP; Pääkkö P
J Pathol; 1992 Sep; 168(1):29-33. PubMed ID: 1333524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
